Pepscope is an innovative biotechnology company founded in 2012 and headquartered in The Netherlands. The company has recently received a significant €4.30M Venture Round investment from Netherlands Enterprise Agency, Oost, and KIKK Capital. Pepscope's proprietary QuantaKinome™ technology enables the development and provision of protein activity phosphoproteomics platforms for Protein Kinase Inhibitor (PKI) developers. This technology aims to enhance the identification of combination therapy, drugs repurpose, and biomarker discovery in the biotechnology, healthcare, and nutrition industries. Their slogan "Kinome Activity Profiling" reflects their commitment to bringing medicines to patients faster by providing valuable insights for drug developers.
No recent news or press coverage available for Pepscope.